Translational Research in Pancreatic Adenocarcinoma
Pancreatic cancer is ranked as the fourth leading cause of cancer-related deaths in the United States despite intensive basic and clinical research over the last decade. In this paper we summarize the Abstracts #176, #234, and #206 presented at the 2014 ASCO Gastrointestinal Cancers Symposium focussing on BRCA 1 and 2 mutations, PABL gene mutations and expression of microRNAs to matrix metalloproteinase. There is an intense need for new findings in the translational research field with prognostic, predictive and therapeutic value.
Image: Survival vs. intensity of microRNA-21 staining plus severity of cancer (Figure 1)
Long, Jiang, et al. "Overcoming Drug Resistance in Pancreatic Cnacer." Expert Opinion on Therapeutic Targets 15.7 (2011): 817-828.
Klein, Alison P. "Genetic Susceptibility to Pancreatic Cancer." Molecular Carcinogenesis 51.1 (2012): 14-24.
Chakraborty, Subhankar, et al. "Current Status of Molecular Markers for Early Detection of Sporadic Pancraetic Cancer." Biochimica et biophysica acta 1815.1 (2011): 44-64.
Koorstra, Jan-Bart M., et al. "Pancreatic Carcinognesis." Pancreatology (2008): 110-125.
Weil, Marcie K. and Alice Chen. "Current Problems in Cancer." PARP Inhibitor Treatment in Ovarian and Breast Cancer 35.1 (2011): 7-50.
Aly, Amal and Shridar Ganesan. "BRCA1, PARP, and 53BP1: conditional synthetic lethatlity and synthetic viability." Journal of Molecular Cell Biology 3 (2011): 66-74.
Sicard, Flavie, et al. "Targeting miR-21 for the Therapy of Pancreatic Cancer." Molecular Therapy 21.5 (2013): 986-994.
Corbo, Vinecenzo, Giampaolo Tortora and Aldo Scarpa. "Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside." Current Drug Targets 13 (2012): 744-752.
Willumsen, Nicholas, et al. "Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patient from healthy controls." BMC Cancer (2013).
Kong, Ziangyu, et al. "Targeted Disruption of Orchestration between stroma and Tumor Cells in Pancreatic cancer: Molecular Basis and Therapeutic Implications." Cytokine and Growth Factor Reviews 23.6 (2012): 343-356.
Lowery, Maeve Aine, et al. "Molecular features of BRCA1/2 and PALB2 mutation associated pancreatic cancer (PAC)." Journal of Clinical Oncology 32 (2014): supple 3; abstract 206.
Morinaga , Soichiro, et al. "MicroRNA-21 ISH analysis to predict DFS in pancreatic cancer patients undergoing adjuvant gemcitabine after curative surgery." Journal of Clinical Oncology 32 (2014): suppl 3; abstract 234.
Heestand, Gregory M., et al. "A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704." Journal of Clinical Oncology 32 (2014): suppl 3; abst 176.
Copyright (c) 2014 Gurbakhash Kaur, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.